Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe and Critical COVID-19 With Refractory Hypoxia

NCT05689008 is registered in ClinicalTrials.gov with Shanghai East Hospital as lead sponsor.

NCT NCT05689008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe and Critical COVID-19 With Refractory Hypoxia
Lead sponsor
Shanghai East Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
January 10, 2023
Completion date
July 30, 2023
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia, mesenchymal stem cell